# Exploring roles of sirtuins in protecting diabetic hearts

> **NIH NIH R01** · UNIVERSITY OF CHICAGO · 2021 · $468,268

## Abstract

Summary: One of the major downsides of improved economy and prosperity is the rise of diabetes-mellitus.
Sedentary life-style and high calorie diet are implicated in the rise of diabetes. Patients with diabetes are at
high risk of developing cardiomyopathy and heart failure (HF). Such patients also experience worst clinical
outcome following, hypertension, myocardial infarction and cardiac surgery. At the cellular level, increased
inflammation, insulin-resistance, cardiac hypertrophy and fibrosis are considered hallmarks of diabetic
cardiomyopathy. However, the underlying mechanism of this disease process is not yet completely
understood, and no targeted therapy is available to treat diabetic cardiomyopathy. New approaches are
needed to understand the mechanism behind this disease, and to identify new therapeutic strategies to
protect the heart from descending to failure post diabetic cardiomyopathy. My laboratory has specific interests
in sirtuins (SIRTs), which are emerging as key regulators of myriad of biological functions, spanning from cell
growth, differentiation to longevity. Recent work from our laboratory has identified SIRT6, as an endogenous
negative regulator of cardiac hypertrophy. In diabetic hearts, we found that SIRT6 levels were drastically
reduced; and this was paralleled with increased expression of activators of fibrosis, inflammasome formation
and insulin-resistance. We also found that SIRT6 deficiency leads to decreased expression of genes needed
to maintain structure and function of mitochondria. These findings led us to hypothesize that decreased SIRT6
levels contribute to the evolution of diabetic cardiomyopathy and subsequent HF. Therefore, a diabetic heart
can be protected from descending to HF by augmenting cardiac SIRT6 levels. We will test this hypothesis in
the following three aims: (Aim 1) Study whether loss of SIRT6 contributes to pathologic changes associated
with the evolution of diabetic cardiomyopathy, and whether SIRT6 overexpressing transgenic mice are
protected from developing HF post diabetes. (Aim 2) Study the underlying mechanism of SIRT6 deficiency
during diabetes, and the mechanism through which SIRT6 maintains mitochondrial health and protects the
heart from developing the disease. (Aim 3) Study whether pharmacological targeting of SIRT6 can protect the
heart from developing diabetic cardiomyopathy and HF. The knowledge gained from completing these aims
will be extremely important to understand what roles sirtuins play in pathogenesis of diabetic cardiomyopathy,
and that could be pertinent to developing new therapies for treatment of HF in diabetic patients.

## Key facts

- **NIH application ID:** 10214667
- **Project number:** 5R01HL136712-04
- **Recipient organization:** UNIVERSITY OF CHICAGO
- **Principal Investigator:** MAHESH P GUPTA
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $468,268
- **Award type:** 5
- **Project period:** 2018-07-15 → 2024-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10214667

## Citation

> US National Institutes of Health, RePORTER application 10214667, Exploring roles of sirtuins in protecting diabetic hearts (5R01HL136712-04). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/10214667. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*